Acute right heart failure in a young person is an unusual presentation and drug overdose is a rare cause. A case is described where the patient presented with striking clinical signs of acute pulmonary hypertension and right heart failure, which were confirmed by transthoracic echocardiography. The precipitating event appeared to be poisoning by tramadol. There were features in keeping with tramadol toxicity and serotonin syndrome. The possible pathophysiology behind the process is discussed.
CASE HISTORY
A 37-year-old woman presented to hospital, via her general practitioner, complaining of weakness, slurred speech and syncope. She had a history of headaches and a chronic pain syndrome and had been prescribed tramadol and nitrazepam. On her arrival, she confided that she had taken ten 200 mg (two grams) slow release tramadol tablets on the previous day. Her partner described her as drowsy since then, requiring assistance to shower, eat and get out of bed, but she had at no stage been unrousable. She had no other medical problems, took no other medicines and was not obese.
On examination she was relatively undistressed but had marked peripheral cyanosis and was hypotensive. Her systolic blood pressure was 68 mmHg (by manual and automated methods), with a regular pulse rate of 92 beats per minute. She had a right ventricular heave and a loud second heart sound in the pulmonary area. In addition to the peripheral cyanosis, the jugular veins were grossly distended and pulsatile and her face was suffused. The chest was clear to auscultation, the respiratory rate 18/minute and SpO 2 was 95% on room air. Her temperature was 37.8°C. The abdomen was generally soft, with a tender pulsatile liver edge, and no other masses.
Specifically there was no peripheral oedema, and the calves were equal in circumference and diffusely tender, as were all muscle groups. There were no stigmata of intravenous drug abuse, no pressure areas, and a careful search by several clinicians found no evidence of any compartment syndrome or trauma. Neurological examination found her to be disorientated but interactive, with tremor, slurred speech and symmetrically dilated pupils. Muscle tone was increased generally, with a global reduction in power in all groups. The reflexes were notably brisk, with ankle clonus and recurrent symmetrical myoclonic jerks of her limbs when startled.
The ECG showed sinus rhythm with a first degree heart block, a rightward axis, an RSR pattern in V1, borderline ST elevation in inferior leads, and inverted T waves in V1 to V3 and inferiorly. The first blood gas was abnormal with a pH of 7.15, P a CO 2 55 mmHg, P a O 2 of 399 mmHg on oxygen via a non-rebreather mask, bicarbonate 18 mmol/l, base deficit 9 mmol/l and potassium 6.9 mmol/l. The chest radiograph was reported as normal, with no regional oligaemia. Serendipitously an echocardiogram was available immediately which demonstrated a left ventricle of normal dimensions and systolic function, but dilated right heart chambers with severe functional tricuspid regurgitation, a deviated interventricular septum and "high" pulmonary artery pressures. The diagnosis of pulmonary embolus was entertained but did not fit well with the presentation. A Doppler leg ultrasound showed no abnormalities, with normally compressible leg veins. A history of anaphylaxis to intravenous contrast medium precluded CT pulmonary angiogram.
From the abnormally raised potassium, phosphate, LDH, ALT and the high creatinine to urea ratio, it was suspected that she had rhabdomyolysis, and this was belatedly confirmed with a CK of 83,000 U/l
The features of right heart failure resolved over many hours, without the need for inotropes. The patient required continuous renal replacement therapy, non-invasive ventilation on day three, and some weeks of further haemodialysis, but is currently well and independent, with no long-term features of pulmonary hypertension. Tramadol and nitrazepam were the only drugs demonstrated on the gas chromatography mass spectrometry (GCMS) drug screen of the initial urine.
DISCUSSION
Tramadol hydrochloride is an atypical analgesic in that it has weak binding to µ-opioid receptors as well as inhibition of serotonin and noradrenaline reuptake. It is this second action that is likely to be of significance in its efficacy, as its analgesic effect is only partly reversed by naloxone and apparently contributes to its adverse reactions and interactions. The product information specifically cautions on the use of tramadol with selective serotonin re-uptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs), and there has been an increasing number of adverse drug reactions involving a suspected serotonin syndrome reported in the literature 1 . The patient denied use of anti-depressants, amphetamines or appetite suppressants and there was no evidence that this patient was exposed to these drugs. While the striking signs of right heart dysfunction predominated in the initial assessment, there were also several features consistent with a severe serotonin syndrome such as rigidity, myoclonus, tremor, clonus, mydriasis, pyrexia and confusion.
Serotonin syndrome is believed to be caused by an excessive stimulation of post-synaptic serotonin receptors located in the lower brainstem (pons and medulla) and spinal cord, where the serotonin 5-HT1A receptor subtype predominates 2 . It is characterized by the rapid onset of cognitive, autonomic and neuromuscular abnormalities 3, 4 . Neuromuscular abnormalities described include restlessness, tremor, hypertonicity, hyperreflexia, myoclonus, ataxia, dyskinesias, opisthotonus, rigidity and rhabdomyolysis 5 . Right heart dysfunction or features of pulmonary hypertension have not previously been described in association with either serotonin syndrome or neuroleptic malignant syndrome.
This patient developed severe rhabdomyolysis. This could have been the result of compression or prolonged immobilization, but the history from her partner and herself, the lack of pressure areas, the absence of a compartment syndrome and the presence of a generalized tenderness and weakness of all muscle groups suggest a widespread process. Serotonin syndrome has previously been described as a cause of rhabdomyolysis and it is the most likely mechanism in this case.
There are three postulated mechanisms by which rhabdomyolysis leads to the development of renal failure: tubular cell damage by free radical oxidant injury and lipid peroxidation by the haem in free myoglobin, tubular obstruction by precipitation of myoglobin, and vasoconstriction due to a number of vasoactive mediators 7 . It might be expected that other reactive vascular beds such as the pulmonary circulation would be affected by the release of intracellular contents, and this could be manifested by raised pulmonary vascular resistance.
The causes of pulmonary hypertension fall into four broad categories: passive increases in pulmonary artery pressures secondary to increased left atrial pressures, veno-occlusive disorders, conditions in which the blood flow through the pulmonary arteries is increased beyond the capacity of the pulmonary circulation to compensate, and conditions associated with vasospasm or occlusion resulting in a diminished effective cross-sectional area of the vascular bed 9, 10 . While there are no descriptions of clinically significant pulmonary hypertension occurring due to rhabdomyolysis or its products, serotonin is certainly implicated in the pathogenesis of both acute and chronic pulmonary hypertension 9-12 .
On a molar basis, serotonin is the most potent pulmonary vasoconstrictor identified to date 10 , and is somewhat unique in that these effects occur at levels which are not much higher than the "resting levels" which are observed in mammalian blood 11 . Chronic use of partial serotonin-agonist drugs such as anorectics and carcinoid tumours are linked to the development of pulmonary hypertension, the subsequent histological changes in the right heart and consequent valvular dysfunction 13, 15 . Serotonin-mediated vasoconstriction of the pulmonary circulation is also suspected in a number of acute pathologies. Endothelial injury and platelet activation resulting from other acute pathologies such as sepsis, septic shock, pulmonary emboli and ARDS are associated with raised serotonin levels and acute pulmonary hypertension. The pulmonary hypertension associated with acute pulmonary embolism is often disproportionate to the degree of vascular occlusion, and is attributed to the vasoconstrictive effects of platelet-derived serotonin.
Irradiation of tissues and treatment with cytotoxic drugs results in release of serotonin as evidenced by direct measurement 14 , and it might be expected that widespread cell destruction and endothelial injury resulting from rhabdomyolysis would result in the same.
The legal and illegal use of drugs with direct or indirect serotonergic effects have been associated with acute pulmonary hypertension, among them cocaine, dopamine, methamphetamine, fluoxetine, sertraline, protamine, tryptophan, pethidine and pentazocine. The mechanism of death in several patients taking anorectics such as aminorex for weight control in the 1960s, and the combination of fenfluramine and phentermine in the 1980s was attributed to serotonin-mediated hyperplasia of vascular myofibroblasts and subsequent pulmonary hypertension and right heart failure 15 .
In this patient, management of serotonin syndrome was overshadowed by the interventions needed for the treatment of the right heart failure and hyperkalaemia, and later her anuric renal failure. The treatment of serotonin syndrome is still largely supportive, with withdrawal of the implicated drugs and attention to temperature control and symptoms. Specific therapies that have been proposed include cyproheptadine, benzodiazepines, propranolol, methysergide, dantrolene, and other drugs with nonspecific anti-serotonin and dopaminergic antagonism such as chlorpromazine and haloperidol. The selflimiting and non-specific symptoms and signs mean that serotonin syndrome is an under-recognised and perhaps misdiagnosed entity with potentially avoidable morbidity. With the increasing use of tramadol for acute and chronic pain in the community and in hospital practice it is likely there will be an increasing incidence of serotonin syndrome.
CONCLUSION
Much of the clinical picture of this case report fitted with a severe serotonin syndrome caused by tramadol, and the rhabdomyolysis was most probably a consequence of this. We consider that the transient acute pulmonary hypertension was due to either a direct serotonin effect on pulmonary vascular resistance or equally possibly due to pulmonary endothelium activation by cell debris and direct pulmonary capillary obstruction. This case would appear to be the first description of acute right heart failure precipitated by a serotonin syndrome.
